OBJECTIVE： To compare the efficacy， safety， vascular endothelial growth factor （VEGF） and matrix metalloproteinase-2 （MMP-2） of docetaxel combined with carboplatin and paclitaxel combined with cisplatin （DDP） in the treatment of advanced ovarian cancer. METHODS： 120 patients with advanced ovarian cancer were randomly divided into docetaxel combined with carboplatin group （60 cases） and paclitaxel combined with DDP group （60 cases）. Docetaxel combined with carboplatin group received 70 mg/m2 Docetaxel injection， intravenous infusion of 1 h， d1； 50 mg/m2 carboplatin injection， intravenous infusion of 1 h， d2. Paclitaxel combined with DDP group received 135 mg/m2 Paclitaxel injection， intravenous infusion of 24 h， d1； 30 mg/m2 DDP for injection， intravenous infusion，d3； 60 mg/m2 Paclitaxel injection （a maximum of 2.0 m2） by intraperitoneal infusion， d8. 3-week was regarded as 1 treatment course， and it lasted 6 courses. Clinical efficacy， VEGF， MMP-2， progression-free survival， overall survival before and after treatment， mortality rate within 2 years of treatment and the incidence of adverse reactions in 2 groups were compared. RESULTS： There were no significant differences in the objective response rate， disease control rate， mortality rate， incidence of adverse reactions between 2 groups （P＞0.05）. The progression-free survival in docetaxel combined with carboplatin group was significantly longer than paclitaxel combined with DDP group， the difference was statistically significant （P＜0.05）. Before treatment， there were no significant differences in VEGF and MMP-2 level between 2 groups （P＞0.05）. After treatment， VEGF and MMP-2 level in 2 groups were significantly lower than before， and VEGF at different time points and MMP-2 level after 4 weeks， 8 weeks and 12 weeks of treatment in docetaxel combined with carboplatin group were lower than paclitaxel combined with DDP group， the differences were statistically significant （P＜0.05）. CONCLUSIONS： Docetaxel combined with carboplatin and paclitaxel combined with DDP shows similar efficacy and safety in the treatment of advanced ovarian cancer， but docetaxel carboplatin combined with is superior to paclitaxel combined with DDP in reducing VEGF and MMP-2 and improving progression-free survival.